Chemoprotective Effect of Plant Phenolics against Anthracycline-induced Toxicity on Rat Cardiomyocytes. Part I. Silymarin and its Flavonolignans

Phytotherapy Research

Volumn 18, Issue 2, 2004, Pages 107-110

  Chlopčíková, Šárka ^a   Psotová, Jitka ^a   Miketová, Petra ^a   Šimánek, Vilím ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

ATP; Chemoprotective activity; Doxorubicin; Flavonolignans; Rat cardiomyocyte; Silymarin

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE ANTIBIOTIC AGENT; DEHYDROSILIBININ; DOXORUBICIN; FLAVONOLIGNAN; IRON; LACTATE DEHYDROGENASE; PHENOL DERIVATIVE; PLANT EXTRACT; PROTECTIVE AGENT; RAZOXANE; SILIBININ; SILIDIANIN; SILYLCHRISTIN; SILYMARIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROTECTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; FRUIT; HEART MUSCLE CELL; HEART PROTECTION; IRON CHELATION; MEMBRANE STABILIZATION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; RAT; SILYBUM MARIANUM;

ANIMALS; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOLIGNANS; FRUIT; MILK THISTLE; MYOCARDIUM; PHYTOTHERAPY; PLANT EXTRACTS; PROTECTIVE AGENTS; RATS; SILYMARIN;

CIRSIUM; SILYBUM MARIANUM;

EID: 1642279578     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1415     Document Type: Article

References (20)

1. Borsari M, Gabbi C, Ghelfi F, et al. 2001. Silybin, a new iron-chelating agent. J Inorg Biochem 85: 123-129.
2. Chlopčíková S, Psotová J, Miketová P. 2001. Neonatal rat cardiomyocytes - a model for the study of morphological, biochemical and electrophysiological characteristics of the heart. Biomed Papers 145: 49-55.
3. Chlopčíková Š, Psotová J, Miketová P, Šimanek V. 2003. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Phenolic acids. Phytother Res, in press.
4. Dorr RT. 1996. Cytoprotective agents for anthracyclines. Semin Oncol 23 (Suppl. 8): 23-34.
5. Dvořák Z, Kosina P, Walterová D, Šimánek V, Bachleda P, Ulrichová J. 2003. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett 137: 201-212.
6. Flora K, Hahn M, Rosen H, Benner K. 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93: 139-143.
7. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. 2002. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124.
8. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. 1990. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmac Ther 47: 219-231.
9. Kuntz E. 1998. Silymarin in the Treatment of Liver Diseases. Falk Foundation: Freiburg; 7-71.
10. Lentzen H, Mengs U, Odenthal K-P. Patent Number: 5,714, 473. Use of Flavolignans as Adjuvants in Tumour Therapy. February 3, 1998.
11. Minotti G, Cairo G, Monti E. 1999. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13: 199-212.
12. Perego P, Corna E, De Cesare M, et al. 2001. Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 8: 31-37.
13. Psotová J, Chlopčíková Š, Grambal F, Šimánek V, Ulrichová J. 2002a. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res 16: S 63-67.
14. Psotová J, Chlopčíková Š, Miketová P. 2002b. Can dexrazoxane be replayed by silibinin in the anthracycline antibiotics therapy? Comparative study in rat cardiomyoyctes. In XI. Biennial Meeting of the Society for Free Radical Research International Pasquier C (ed.). Monduzzi Editore S.p.A. Medimond Inc: Bologna; 711-715.
15. Saller R, Meier R, Brignoli R. 2001. The use of silymarin in the treatment of liver diseases. Drugs 61: 2035-2063.
16. Šimánek V, Škottová N, Bartek J, et al. 2001. Extract from Silybum marianum as a nutraceutical: a double-blind placebo-controlled study in healthy young men. Czech J Food Sci 19: 106-110.
17. Šimánek V, Walterová D, Vičar J, et al. 2001. Silymarin - an extract from the milk thistle (Silybum marianum) - is it a drug or nutritional supplement? Česká Slov Farm 50: 66-69.
18. Škottová N, Krečman V, Šimánek V. 1999. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res 13: 535-557.
19. 2+ pump. Kinetics and structure-function relationships. Biochem Pharmacol 41: 669-675.
20. Wellington K, Jarvis B. 2001. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 15: 465-489.